DiscGenics Joins MedCision’s ThawSTAR Early Adopter Program for Cell Therapy Clinical Trials

MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and DiscGenics, Inc., a regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that DiscGenics has joined MedCision’s ThawSTAR Clinical Early Adopter Program. 

DiscGenics Receives FDA Allowance of IND to Commence Clinical Study of Its Degenerative Disc Disease Therapy

DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, is pleased to announce that it has been notified by the U.S. Food and Drug Administration (FDA) that an Investigational New Drug (IND) Application for a clinical study of its first product candidate, IDCT, may proceed.

DiscGenics Successfully Extends Its IP Coverage Internationally

DiscGenics, Inc. (DiscGenics) announced today that its initial patent has been granted in four key international markets including Europe, Japan, China, and Israel. The issuance of this patent abroad extends the protection of the company's domestic intellectual property (IP) into major international markets. The European patent has also been validated in the key strategic European countries. Additional applications in other key global markets are pending to ensure broad coverage of DiscGenics' IP.